Skip to main content

Allergan Value Stock - Dividend - Research Selection

Allergan

ISIN: IE00BY9D5467, WKN: A14U12

Market price date: 30.11.-0001
Market price: 0,00 USD


Allergan Fundamental data and company key figures of the share

Annual reports in USD
Key figures 22-03-2020
Cash flow
Net operating cash flow 7.238.700.000
Capital Expenditures -433.500.000
Free cash flow 6.805.199.872
Balance sheet
Total Equity 58.173.600.000
Liabilities & Shareholders equity 94.699.100.000
Income statement
Net income -5.271.000.000
Eps (diluted) -16,020
Diluted shares outstanding 329.026.000
Net sales/revenue 16.088.900.000

Fundamental ratios calculated on: 30-11--0001

Ratios
Key figures 30-11--0001
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI0,00
ROE0,00
Income statement
P/E0,00
Div. Yield0,00%
P/B0,00
P/S0,00


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolAGN
Market Capitalization63.508.598.784,00 USD
Country
IndicesMSCI World Index
Sectors
Raw Data Source
Stock Split
Internetwww.allergan.com


Description of the company

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company's segments include specialty pharmaceuticals, which produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologic products and the medical devices segment, which produces a range of medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders; obesity intervention products, and facial aesthetics products. In December 2013, Allergan Inc completed the sale of its obesity intervention business to Apollo Endosurgery.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.allergan.com


NEWS


Why XPEL Is Poised to Avoid Dreaded Supply Chain Issues

2021-12-22
In this segment of "Industry Focus" on Motley Fool Live, recorded on Dec. 2, Fool analysts Nick Sciple and Auri Hughes discuss the strong relationship that XPEL (NASDAQ: XPEL) has with its main supplier.